New treatment effective at reversing the manifestations of thyroid eye disease

New treatment effective at reversing the manifestations of thyroid eye disease

Patients received the drug intravenously once every week for three weeks over a 21-week period. Results showed: Patients who were administered teprotumumab experienced effective response in two doses or six weeks of administration. After 24 weeks, the study showed 83% of people on the drug had measurable reduction in eye bulge versus 10% of those on a placebo. The overall response rate was 78% among those taking the drug compared to 7% of people taking a placebo. The new discovery contributed to the fast track drug approval by the U.S. Food and Drug Administration, marketed under the brand name Tepezza, making it the first drug approved for the condition. "Other than highly invasive surgical procedures, patients with thyroid eye disease had no real treatment alternatives," Douglas said. "This is a medical breakthrough for a very large percentage of the patient population to receive an alternative medical infusion treatment with great results, quickly." Teprotumumab is a fully human monoclonal antibody which blocks the inflammatory autoimmune pathophysiology that underlies thyroid eye disease. "This treatment has the potential to alter the course of the disease, potentially sparing patients from needing multiple invasive surgeries by providing an alternative, nonsurgical treatment option," said Wiley Chambers, M.D., deputy director of the Division of Transplant and Ophthalmology Products in the FDA's Center for Drug Evaluation and Research. Source:



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More